Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-12-31
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study plans to learn if the EvoEndo Endoscopy system can be used to evaluate, provide and follow up care for upper gastrointestinal tract diseases in the bariatric population. The smallest current scope available for such a technique is an adult transnasal endoscope with a larger diameter, a pulmonary bronchoscope or Ear Nose and Throat (ENT) laryngoscope. This study is evaluating a newly Food and Drug Administration (FDA) cleared ultra-slim, single-use, endoscope specifically designed for transnasal endoscopy to evaluate its use in adult upper tract gastrointestinal diseases. If such a technique is successful it could improve the safety, cost, and access of endoscopic care for patients in need of an endoscopic evaluation for a bariatric medical condition.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry
NCT04494048
Obesity
Weight Loss
Gastro Esophageal Reflux
+1 more
RECRUITING
Benefits of Endoscopic Bariatric Procedures
NCT05514288
Obesity
RECRUITING
NA
ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
NCT02518685
Obesity
COMPLETED
NA
A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects
NCT01386905
Obesity
COMPLETED
NA
Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity
NCT02191501
Obesity
Over Weight
TERMINATED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Oral sedated endoscopy of the upper gastrointestinal tract as Esophagogastroduodenoscopy (EGD) has been time tested and effective, but poses enhanced risk in the bariatric population. In the adult population nasal rather than orally guided EGD is available without sedations. This is known as transnasal endoscopy (TNE). Adult studies have demonstrated its feasibility, more rapid implementation, a possibility for increased endoscopy access, and enhanced safety for its use in multiple upper gastrointestinal tract disease, however it has not been readily adopted in the United States using standard 5-6 mm transnasal endoscopes.
Generally, having only sedated oral upper tract endoscopy using a typical 9-10 mm endoscope available in the United States has created problems with increasing costs, delayed diagnosis, endoscopy access issues, and morbidity around upper gastrointestinal tract disease. In a bariatric and metabolic program this can also delay care and timely intervention to allow for weight loss and improved morbidity. The recent COVID-19 pandemic has also hindered access to general diagnostic endoscopy and the referrals from bariatric programs could also prevent access for other general diagnostic screening or surveillance endoscopy not in the bariatric population. Additionally, the total cost of a sedated EGD can exceed $10,000 due to the cost of anesthesia. In high-risk populations such as the elderly and individuals with increased body mass index (BMI), the use of endotracheal tubes and deep sedation can lead to aspiration, atelectasis, or pneumonia. Most recently Friedlander and Nguyen et al published reports on the increased use of sedation-free endoscopy using even smaller endoscopes for primarily Eosinophilic esophagitis (EoE) but also a variety of diseases. Additionally, DeBoer et al published on the use of TNE in bariatric endoscopic screening and showed success and lower costs in an adult population. EvoEndo, Inc. has developed and introduced an FDA cleared 3.5 mm, portable, single-use endoscopy system that enables transnasal endoscopy of the upper GI tract with mucosal biopsies. It has the potential to more broadly introduce enhanced sedation-free endoscopic options for high risk patients in need of endoscopic screening for bariatric conditions in the United States. This study aims to evaluate the introduction of sedation-free TNE to an ambulatory bariatric clinic and evaluate its impact on time to diagnosis, time to intervention, impact on patient (direct/indirect) and clinic costs (direct/indirect) and revenue and the provider/team experience introducing the system.
Generally, having only sedated oral upper tract endoscopy using a typical 9-10 mm endoscope available in the United States has created problems with increasing costs, delayed diagnosis, endoscopy access issues, and morbidity around upper gastrointestinal tract disease. In a bariatric and metabolic program this can also delay care and timely intervention to allow for weight loss and improved morbidity. The recent COVID-19 pandemic has also hindered access to general diagnostic endoscopy and the referrals from bariatric programs could also prevent access for other general diagnostic screening or surveillance endoscopy not in the bariatric population. Additionally, the total cost of a sedated EGD can exceed $10,000 due to the cost of anesthesia. In high-risk populations such as the elderly and individuals with increased body mass index (BMI), the use of endotracheal tubes and deep sedation can lead to aspiration, atelectasis, or pneumonia. Most recently Friedlander and Nguyen et al published reports on the increased use of sedation-free endoscopy using even smaller endoscopes for primarily Eosinophilic esophagitis (EoE) but also a variety of diseases. Additionally, DeBoer et al published on the use of TNE in bariatric endoscopic screening and showed success and lower costs in an adult population. EvoEndo, Inc. has developed and introduced an FDA cleared 3.5 mm, portable, single-use endoscopy system that enables transnasal endoscopy of the upper GI tract with mucosal biopsies. It has the potential to more broadly introduce enhanced sedation-free endoscopic options for high risk patients in need of endoscopic screening for bariatric conditions in the United States. This study aims to evaluate the introduction of sedation-free TNE to an ambulatory bariatric clinic and evaluate its impact on time to diagnosis, time to intervention, impact on patient (direct/indirect) and clinic costs (direct/indirect) and revenue and the provider/team experience introducing the system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Obesity
Obesity, Morbid
Obese
GI Disorders
Gastrointestinal Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Case Control
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transnasal Endoscopy (TNE)
Unsedated endoscopic evaluation of the esophagus and stomach through the nose with a transnasal endoscope.
Group Type
ACTIVE_COMPARATOR
Transnasal Endoscopy
Intervention Type
DEVICE
Unsedated endoscopic evaluation through the nose.
Sedated Esophagogastroduodenoscopy (EGD)
Sedated endoscopic evaluation of the esophagus and stomach through the mouth with a standard upper endoscope.
Group Type
ACTIVE_COMPARATOR
Esophagogastroduodenoscopy
Intervention Type
PROCEDURE
Sedated endoscopic evaluation through the mouth.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transnasal Endoscopy
Unsedated endoscopic evaluation through the nose.
Intervention Type
DEVICE
Esophagogastroduodenoscopy
Sedated endoscopic evaluation through the mouth.
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
TNE
EGD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patient 18 years of age and less than 90 years of age with clinically referred for esophagoscopy, gastroscopy, or esophagogastroduodenoscopy (EGD)
2. Cared for in metabolic and bariatric clinic
2. Cared for in metabolic and bariatric clinic
Exclusion Criteria
1. Patient \<18 years of age
2. Medically contraindicated to perform EGD or TNE
3. Inability to provide informed consent
2. Medically contraindicated to perform EGD or TNE
3. Inability to provide informed consent
Minimum Eligible Age
18 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EvoEndo, Inc.
UNKNOWN
Sponsor Role
collaborator
Christopher C. Thompson, MD, MSc
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher C. Thompson, MD, MSc
Director of Endoscopy
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher C. Thompson, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
Brigham and Womens Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Slater BJ, Collings A, Dirks R, Gould JC, Qureshi AP, Juza R, Rodriguez-Luna MR, Wunker C, Kohn GP, Kothari S, Carslon E, Worrell S, Abou-Setta AM, Ansari MT, Athanasiadis DI, Daly S, Dimou F, Haskins IN, Hong J, Krishnan K, Lidor A, Litle V, Low D, Petrick A, Soriano IS, Thosani N, Tyberg A, Velanovich V, Vilallonga R, Marks JM. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). Surg Endosc. 2023 Feb;37(2):781-806. doi: 10.1007/s00464-022-09817-3. Epub 2022 Dec 18.
Reference Type
BACKGROUND
Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, Schofield M, Barlow SE, Aronne L. White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources. Clin Gastroenterol Hepatol. 2017 May;15(5):631-649.e10. doi: 10.1016/j.cgh.2016.10.023. Epub 2017 Feb 27.
Reference Type
BACKGROUND
American Societyfor Gastrointestinal Endoscopy Standards of Practice Committee; Evans JA, Muthusamy VR, Acosta RD, Bruining DH, Chandrasekhara V, Chathadi KV, Eloubeidi MA, Fanelli RD, Faulx AL, Fonkalsrud L, Khashab MA, Lightdale JR, Pasha SF, Saltzman JR, Shaukat A, Wang A, Stefanidis D, Richardson WS, Kothari SN, Cash BD. The role of endoscopy in the bariatric surgery patient. Gastrointest Endosc. 2015 May;81(5):1063-72. doi: 10.1016/j.gie.2014.09.044. Epub 2015 Feb 27. No abstract available.
Reference Type
BACKGROUND
Kolb JM, Han S, Scott FI, Murphy CC, Hosokawa P, Wani S; Early Onset Esophageal Adenocarcinoma Study Group. Early-Onset Esophageal Adenocarcinoma Presents With Advanced-Stage Disease But Has Improved Survival Compared With Older Individuals. Gastroenterology. 2020 Dec;159(6):2238-2240.e4. doi: 10.1053/j.gastro.2020.08.002. Epub 2020 Aug 8. No abstract available.
Reference Type
BACKGROUND
Thrift AP. Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? Dig Dis Sci. 2018 Aug;63(8):1988-1996. doi: 10.1007/s10620-018-5068-6.
Reference Type
BACKGROUND
Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015 Aug;149(2):302-17.e1. doi: 10.1053/j.gastro.2015.04.053. Epub 2015 May 7.
Reference Type
BACKGROUND
Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022 Apr 1;117(4):559-587. doi: 10.14309/ajg.0000000000001680.
Reference Type
BACKGROUND
ASGE STANDARDS OF PRACTICE COMMITTEE; Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, Agrawal D, Buxbaum JL, Fishman DS, Gurudu SR, Jue TL, Kripalani S, Lee JK, Khashab MA, Naveed M, Thosani NC, Yang J, DeWitt J, Wani S; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. doi: 10.1016/j.gie.2019.05.012. No abstract available.
Reference Type
BACKGROUND
Muthusamy VR, Wani S, Gyawali CP, Komanduri S; CGIT Barrett's Esophagus Consensus Conference Participants. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2696-2706.e1. doi: 10.1016/j.cgh.2022.06.003. Epub 2022 Jul 3.
Reference Type
BACKGROUND
Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA; American College of Gastroenterology. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013 May;108(5):679-92; quiz 693. doi: 10.1038/ajg.2013.71. Epub 2013 Apr 9.
Reference Type
BACKGROUND
Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, Masterson JC, Ochkur S, Protheroe C, Moore W, Pan Z, Amsden K, Robinson Z, Capocelli K, Mukkada V, Atkins D, Fleischer D, Hosford L, Kwatia MA, Schroeder S, Kelly C, Lovell M, Melin-Aldana H, Ackerman SJ. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013 Oct;62(10):1395-405. doi: 10.1136/gutjnl-2012-303171. Epub 2012 Aug 15.
Reference Type
BACKGROUND
Dumortier J, Ponchon T, Scoazec JY, Moulinier B, Zarka F, Paliard P, Lambert R. Prospective evaluation of transnasal esophagogastroduodenoscopy: feasibility and study on performance and tolerance. Gastrointest Endosc. 1999 Mar;49(3 Pt 1):285-91. doi: 10.1016/s0016-5107(99)70002-7.
Reference Type
BACKGROUND
Dumortier J, Josso C, Roman S, Fumex F, Lepilliez V, Prost B, Lot M, Guillaud O, Petit-Laurent F, Lapalus MG, Ponchon T. Prospective evaluation of a new ultrathin one-plane bending videoendoscope for transnasal EGD: a comparative study on performance and tolerance. Gastrointest Endosc. 2007 Jul;66(1):13-9. doi: 10.1016/j.gie.2006.11.058.
Reference Type
BACKGROUND
Birkner B, Fritz N, Schatke W, Hasford J. A prospective randomized comparison of unsedated ultrathin versus standard esophagogastroduodenoscopy in routine outpatient gastroenterology practice: does it work better through the nose? Endoscopy. 2003 Aug;35(8):647-51. doi: 10.1055/s-2003-41523.
Reference Type
BACKGROUND
Mokhashi MS, Wildi SM, Glenn TF, Wallace MB, Jost C, Gumustop B, Kim CY, Cotton PB, Hawes RH. A prospective, blinded study of diagnostic esophagoscopy with a superthin, stand-alone, battery-powered esophagoscope. Am J Gastroenterol. 2003 Nov;98(11):2383-9. doi: 10.1111/j.1572-0241.2003.08701.x.
Reference Type
BACKGROUND
Yagi J, Adachi K, Arima N, Tanaka S, Ose T, Azumi T, Sasaki H, Sato M, Kinoshita Y. A prospective randomized comparative study on the safety and tolerability of transnasal esophagogastroduodenoscopy. Endoscopy. 2005 Dec;37(12):1226-31. doi: 10.1055/s-2005-921037.
Reference Type
BACKGROUND
Hu CT. Gauze pledgetting versus endoscopic-guided aerosolized spray for nasal anesthesia before transnasal EGD: a prospective, randomized study. Gastrointest Endosc. 2010 Jan;71(1):11-20. doi: 10.1016/j.gie.2009.06.016. Epub 2009 Sep 12.
Reference Type
BACKGROUND
Mulcahy HE, Riches A, Kiely M, Farthing MJ, Fairclough PD. A prospective controlled trial of an ultrathin versus a conventional endoscope in unsedated upper gastrointestinal endoscopy. Endoscopy. 2001 Apr;33(4):311-6. doi: 10.1055/s-2001-13692.
Reference Type
BACKGROUND
Gardner JG, Feld LD. The impact of COVID-19 on endoscopy and cancer screening: a focus on access and equity. Therap Adv Gastroenterol. 2023 May 10;16:17562848231173334. doi: 10.1177/17562848231173334. eCollection 2023.
Reference Type
BACKGROUND
Nguyen N, Lavery WJ, Capocelli KE, Smith C, DeBoer EM, Deterding R, Prager JD, Leinwand K, Kobak GE, Kramer RE, Menard-Katcher C, Furuta GT, Atkins D, Fleischer D, Greenhawt M, Friedlander JA. Transnasal Endoscopy in Unsedated Children With Eosinophilic Esophagitis Using Virtual Reality Video Goggles. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2455-2462. doi: 10.1016/j.cgh.2019.01.023. Epub 2019 Jan 29.
Reference Type
BACKGROUND
Pouwels S, Buise MP, Twardowski P, Stepaniak PS, Proczko M. Obesity Surgery and Anesthesiology Risks: a Review of Key Concepts and Related Physiology. Obes Surg. 2019 Aug;29(8):2670-2677. doi: 10.1007/s11695-019-03952-y.
Reference Type
BACKGROUND
Lieber SR, Heller BJ, Martin CF, Howard CW, Crockett S. Complications of Anesthesia Services in Gastrointestinal Endoscopic Procedures. Clin Gastroenterol Hepatol. 2020 Aug;18(9):2118-2127.e4. doi: 10.1016/j.cgh.2019.10.011. Epub 2019 Oct 14.
Reference Type
BACKGROUND
Friedlander JA, DeBoer EM, Soden JS, Furuta GT, Menard-Katcher CD, Atkins D, Fleischer DM, Kramer RE, Deterding RR, Capocelli KE, Prager JD. Unsedated transnasal esophagoscopy for monitoring therapy in pediatric eosinophilic esophagitis. Gastrointest Endosc. 2016 Feb;83(2):299-306.e1. doi: 10.1016/j.gie.2015.05.044. Epub 2015 Jul 2.
Reference Type
BACKGROUND
Grant RK, Brindle WM, Robertson AR, Kalla R, Plevris JN. Unsedated Transnasal Endoscopy: A Safe, Well-Tolerated and Accurate Alternative to Standard Diagnostic Peroral Endoscopy. Dig Dis Sci. 2022 Jun;67(6):1937-1947. doi: 10.1007/s10620-022-07432-9. Epub 2022 Mar 3.
Reference Type
BACKGROUND
DeBoer AM, Mellion KM, Frankki SM, Kallies KJ, Grover BT, Pfeiffer JD, Kothari SN. Pre-screening for bariatric surgery patients: comparative effectiveness of transnasal endoscopy versus esophagogastroduodenoscopy. Surg Endosc. 2021 Aug;35(8):4153-4159. doi: 10.1007/s00464-020-07892-y. Epub 2020 Aug 14.
Reference Type
BACKGROUND
ASGE Technology Committee; Rodriguez SA, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, Kwon RS, Mamula P, Pedrosa MC, Varadarajulu S, Song LM, Tierney WM. Ultrathin endoscopes. Gastrointest Endosc. 2010 May;71(6):893-8. doi: 10.1016/j.gie.2010.01.022. No abstract available.
Reference Type
BACKGROUND
Lin LF, Shen HC. Unsedated transnasal percutaneous endoscopic gastrostomy carried out by a single physician. Dig Endosc. 2013 Mar;25(2):130-5. doi: 10.1111/j.1443-1661.2012.01350.x. Epub 2012 Jul 10.
Reference Type
BACKGROUND
Nguyen N, Mark J, Furuta GT. Emerging Role of Transnasal Endoscopy in Children and Adults. Clin Gastroenterol Hepatol. 2022 Mar;20(3):501-504. doi: 10.1016/j.cgh.2021.11.021. Epub 2021 Dec 16. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023P002683
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Liraglutide on Body Surface Gastric Mapping
NCT06500130
COMPLETED
NA
National Registry of Obesity Treatment by Endosleeve
NCT06657339
NOT_YET_RECRUITING
Use of an Endoluminal-suturing Device for Endoscopic Gastric Reduction as an Aid for Class I Obesity, or Class II Obesity Without Comorbidity
NCT03900481
TERMINATED
NA
Endoscopic Sleeve Gastroplasty for Treatment of Obesity
NCT02231970
UNKNOWN
NA
Multi-Center Pre-Bariatric Weight Loss Study
NCT00469391
COMPLETED
PHASE2
US-guided Airway Nerve Block vs. Topical Lidocaine in Video Laryngoscopy for Difficult Bariatric Intubation.
NCT07069686
COMPLETED
NA
Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity
NCT05713071
ACTIVE_NOT_RECRUITING
NA
Bariatric Electrical Impedance Tomography
NCT05187039
COMPLETED
Gastric Ultrasound in Patients Who Have Undergone Bariatric Surgery
NCT07310875
NOT_YET_RECRUITING
NA
Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma
NCT01025076
COMPLETED
PHASE2
Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity
NCT06339320
RECRUITING
NA
Endoscopic Gastric Reduction for Weight Management
NCT01682733
COMPLETED
PHASE1
Study for Short Term Weight Loss in Candidates for Bariatric Surgery
NCT00985491
COMPLETED
PHASE2
Gastric Emptying Using Two Imaging Methods for Those Who Have Undergone POSE2 Weight Loss Procedure
NCT04502732
TERMINATED
The Lowering Weight in Severe Obesity by Embolization of the Gastric Artery Trial
NCT03185949
COMPLETED
NA
Influence of Central Obesity on the Esophageal Epithelial Barrier
NCT02776982
COMPLETED
NA
ESG in Obese Adolescents
NCT06914765
ENROLLING_BY_INVITATION
NA
A Prospective Study to Evaluate the Suture Pattern With the Endomina Suturing Device for Endoscopic Sutured Gastroplasty (ESG).
NCT03843801
COMPLETED
NA
A Feasibility Study for the Treatment of Primary Obesity Cross-over Arm
NCT05939973
UNKNOWN
NA
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy
NCT05486338
ACTIVE_NOT_RECRUITING
NA
Endostapler Sleeve Gastrectomy Study
NCT04617574
COMPLETED
Gastric and Autonomic Functions in Patients With Intragastric Balloon
NCT03530410
WITHDRAWN
A UK Registry for Metabolic and Bariatric Endoscopic Interventions
NCT06305208
RECRUITING
Cryo Balloon for Residual Barrett's Esophagus
NCT02230410
COMPLETED
NA
Feasibility and Safety of Robotic Bariatric Surgery Using the SenhanceTM Surgical System
NCT05208138
TERMINATED
PHASE2